Dyne Therapeutics Appoints Vikram Karnani to Board of Directors

WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Vikram Karnani to its Board of Directors. Mr. Karnani brings extensive commercial and executive leadership experience in rare disease and biopharmaceuticals, serving as the current chief executive officer of Collegium Pharmaceutical and having spent nearly a decade leading several lines of business and functions at Horizon Therapeutics.

“We are pleased to welcome Vikram to our Board as we advance toward commercialization,” said Jason Rhodes, chairman of Dyne’s Board of Directors and partner at Atlas Venture. “As a CEO and former commercial leader of a biotechnology company that grew quickly and successfully, Vikram brings valuable experience in launching products, driving growth, and realizing value. His insights will further Dyne’s progress toward generating revenue and expanding our portfolio.”

“Throughout my career, I’ve focused on translating innovation into highly successful businesses that unlock value and improve the lives of patients,” said Vikram Karnani. “Dyne’s clinically validated drug delivery approach and progress towards commercialization underscore its potential to deliver meaningful functional improvement for people living with neuromuscular diseases. I’m excited to join the Board at this pivotal stage as the company works to realize its full potential and build shareholder value.”

“Vikram’s track record of running world-class commercial and medical organizations will add an important perspective to our Board as we prepare for our first potential launch in Q1 2027,” said John Cox, president and chief executive officer of Dyne. “His experience leading rare disease portfolios, particularly through periods of rapid growth, aligns exceptionally well with our goal of building a commercial company with multiple opportunities to create value and potentially transform care for neuromuscular diseases.”

Mr. Karnani has served as president and chief executive officer of Collegium Pharmaceutical since November 2024. Collegium is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, with a leading portfolio in responsible pain management and a growing neuropsychiatry business. Prior to joining Collegium, he was executive vice president and president, global commercial operations and medical affairs (rare disease) at Amgen where he led the integration and growth of the company’s approximately $4 billion rare disease business following the $28 billion acquisition of Horizon Therapeutics. During nearly a decade at Horizon, Mr. Karnani held multiple senior executive roles, including president of global commercial operations and chief commercial officer, where he helped transform the company from a $500 million in revenue enterprise into a rare disease leader generating more than $3 billion in revenue through disciplined strategy, M&A, capital deployment and commercialization. Earlier in his career, Mr. Karnani served as vice president of the therapeutics and cell therapy business and held leadership roles in strategy and business development at Fresenius Kabi. 

Mr. Karnani holds a bachelor’s degree in electrical engineering from the University of Mumbai, a master’s degree in electrical engineering from Case Western Reserve University and an MBA from Northwestern University’s Kellogg School of Management.

About Dyne Therapeutics

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more , and follow us on , and .

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne’s strategy, future operations, prospects and plans, objectives of management, the potential of the FORCE^TM platform, expectations regarding the timing and outcome of interactions with and submissions to global regulatory authorities and anticipated timelines for submission for regulatory approval and launch of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “will,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Dyne’s ability to enroll patients in clinical trials; whether results from preclinical studies and initial data from early clinical trials will be predictive of the final results of the clinical trials or future trials; uncertainties as to the FDA’s and other regulatory authorities’ interpretation of the data from Dyne's clinical trials and acceptance of Dyne's clinical programs and the regulatory approval process, including the availability of accelerated approval pathways; whether Dyne’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Dyne’s filings with the Securities and Exchange Commission (SEC), including the Company’s most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne’s views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release.

Contacts:

Investors

Mia Tobias



781-317-0353



Media

Stacy Nartker



781-317-1938